SARS-CoV-2 vaccines: a triumph of science and collaboration

Golob, Jonathan L.; Lugogo, Njira L; Lauring, Adam S.; Lok, Anna S.

doi:10.1172/jci.insight.149187

Cited by 92 publications

(89 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, such a vaccine platform carrying a foreign antigen could be used in a combination or as a boost for vaccines with a negligent or absent T cell response induction. The current SARS-CoV-2 vaccines approved for human use induce protection associated with high S/RBD-specific antibody levels, which lasts up to several months [ 5 ]. It is still not known whether long-lasting protective immunity will be generated with the current SARS-CoV-2 vaccines in use.…”

Section: Discussionmentioning

confidence: 99%

“…The neutralizing (Ne) antibodies against SARS-CoV-2 RBD are considered the main correlates of protection from infection and disease [ 4 ]. All vaccines currently used to mass immunize the human population, including mRNA-based BNT162 (Pfizer/BioNTech, Mainz, Germany) and mRNA-1273 (Moderna, Inc., Cambridge, MA, USA) or adenovirus vector-based AZD1222 (Oxford/AstraZeneca, Cambridge, UK), induce high levels of Ne antibodies up to several months after the vaccination [ 5 ]. However, it is still unknown whether long-lasting and cross-protective immunity against newly emerging SARS-CoV-2 variants of concern [ 6 ] will be generated with the currently available vaccines.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses

et al. 2021

View full text Add to dashboard Cite

Vaccines based on mRNA and viral vectors are currently used in the frontline to combat the ongoing pandemic caused by the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). However, there is still an urgent need for alternative vaccine technologies inducing/boosting long-lasting and cross-reactive immunity in different populations. As a possible vaccine candidate, we employed the rotavirus VP6-protein platform to construct a fusion protein (FP) displaying receptor-binding domain (RBD) of SARS-CoV-2 spike protein (S) at the N-terminus of VP6. The recombinant baculovirus-insect cell produced VP6-RBD FP was proven antigenic in vitro and bound to the human angiotensin-converting enzyme 2 (hACE2) receptor. The FP was used to immunize BALB/c mice, and humoral- and T cell-mediated immune responses were investigated. SARS-CoV-2 RBD-specific T cells were induced at a high quantity; however, no RBD or S-specific antibodies were detected. The results suggest that conformational B cell epitopes might be buried inside the VP6, while RBD-specific T cell epitopes are available for T cell recognition after the processing and presentation of FP by the antigen-presenting cells. Further immunogenicity studies are needed to confirm these findings and to assess whether, under different experimental conditions, the VP6 platform may present SARS-CoV-2 antigens to B cells as well.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The issue of potential mutagenesis has also been underlined; it is considered that oligonucleotide-based therapeutic agents do not pose a threat to genomic integrity, unlike usage of lentiviral vectors. Today, the new experience is being gained in the field of RNA-based therapies due to investigations upon vaccines against SARS-CoV2 which use either artificial nano-encapsulated mRNA strands or viral vectors [ 173 ].…”

Section: Challenges In Therapies Aimed To Ncrnamentioning

confidence: 99%

Therapies Targeted at Non-Coding RNAs in Prevention and Limitation of Myocardial Infarction and Subsequent Cardiac Remodeling—Current Experience and Perspectives

Kowara

Borodzicz-Jażdżyk

Rybak

et al. 2021

IJMS

View full text Add to dashboard Cite

Myocardial infarction is one of the major causes of mortality worldwide and is a main cause of heart failure. This disease appears as a final point of atherosclerotic plaque progression, destabilization, and rupture. As a consequence of cardiomyocytes death during the infarction, the heart undergoes unfavorable cardiac remodeling, which results in its failure. Therefore, therapies aimed to limit the processes of atherosclerotic plaque progression, cardiac damage during the infarction, and subsequent remodeling are urgently warranted. A hopeful therapeutic option for the future medicine is targeting and regulating non-coding RNA (ncRNA), like microRNA, circular RNA (circRNA), or long non-coding RNA (lncRNA). In this review, the approaches targeted at ncRNAs participating in the aforementioned pathophysiological processes involved in myocardial infarction and their outcomes in preclinical studies have been concisely presented.

show abstract

“…But usually, vaccine development involves 5 to 10 years to get approval, in the best scenarios, which is not fast enough to hinder fast-spreading pathogens, like SARS-CoV-2. In the process of approval, it is necessary that the vaccine passes through three phases of clinical trials and ultimately, through regulatory approval 8,9 .…”

Section: Diversity In Vaccine Formulations: a Biotechnological Response To Varied Pathogensmentioning

confidence: 99%

Properties and Mechanisms of Action of Non-Replicative Viral Vectors, Inactivated Viruses, Rna and Dna Vaccines

Durán-Méndez¹,

Tobón-Cubillos²,

Viveros-Hernández³

et al. 2021

Rev Soc Esp Bene

View full text Add to dashboard Cite

show abstract

SARS-CoV-2 vaccines: a triumph of science and collaboration

Abstract: NL receives research support from Astra-Zeneca and Janssen for SARS-CoV-2 vaccine trials. ASL receives research support from TARGET RWE for studies on nonalcoholic fatty liver disease, hepatitis B and primary biliary cholangitis.

Cited by 92 publications

References 52 publications

Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses

Fusion Protein of Rotavirus VP6 and SARS-CoV-2 Receptor Binding Domain Induces T Cell Responses

Therapies Targeted at Non-Coding RNAs in Prevention and Limitation of Myocardial Infarction and Subsequent Cardiac Remodeling—Current Experience and Perspectives

Properties and Mechanisms of Action of Non-Replicative Viral Vectors, Inactivated Viruses, Rna and Dna Vaccines

Contact Info

Product

Resources

About